In a recent development, Johnson & Johnson, the multinational corporation known for its consumer medical and pharmaceutical goods, has come forward with a bankruptcy plan valued at $6.48 billion. The plan is proposed as a solution for the numerous talc lawsuits which the company has been struggling with for years now. Supposedly, it will help resolve the issue and avoid further legal turmoil.
Despite the company’s proposal, this resolution is far from being finalized. Representative lawyers for the victims of ovarian cancer, one of the crucial plaintiff groups in these talc lawsuits, have been quick to challenge the proposition. A prime example is Andy Birchfield from Beasley Allen, who sharply criticized the plan. His words serve as a stark reminder that there is staunch opposition against the proposal. He told Law.com, “This is not a done deal. There is substantial opposition to this.”
While the precise terms of the bankruptcy plan are yet to be disclosed in full, it’s clear that the corporation is attempting to pull itself out of the mire of legal disgruntlement and direct its energy towards growth and product innovation. However, with such prominent opposition waiting in the wings, the fate of Johnson & Johnson’s bankruptcy proposal seems uncertain at best.